Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
Results to Inform Development Plan and Dose Selection for Phase 3
LONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it has randomized the last patient in its Phase 2b dose-ranging study evaluating the effect of nebulized ensifentrine as an add-on to treatment with a long acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease (“COPD”).
Ensifentrine has the potential to be the first novel class of bronchodilator in over 40 years, and the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The addition of nebulized ensifentrine to symptomatic COPD patients already treated with standard-of-care medicines represents a significant market opportunity.
Highlights:
- Enrollment completed on schedule with data expected around year end 2019
- Preparations underway for End-of-Phase 2 meeting with the U.S. FDA expected in the first half of 2020
- Commencement of Phase 3 trials expected in 2020
